| Stat3 and Stat4 direct development of IL-17-secreting Th cells AN Mathur, HC Chang, DG Zisoulis, GL Stritesky, Q Yu, JT O’Malley, ... The Journal of Immunology 178 (8), 4901-4907, 2007 | 719 | 2007 |
| Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism Y Pan, T Tian, CO Park, SY Lofftus, S Mei, X Liu, C Luo, JT O’Malley, ... Nature 543 (7644), 252-256, 2017 | 612 | 2017 |
| Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo … AS Paller, EC Siegfried, D Thaçi, A Wollenberg, MJ Cork, PD Arkwright, ... Journal of the American Academy of Dermatology 83 (5), 1282-1293, 2020 | 294 | 2020 |
| Clinically resolved psoriatic lesions contain psoriasis-specific IL-17–producing αβ T cell clones TR Matos, JT O’Malley, EL Lowry, D Hamm, IR Kirsch, HS Robins, ... The Journal of clinical investigation 127 (11), 4031-4041, 2017 | 251 | 2017 |
| TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL IR Kirsch, R Watanabe, JT O’Malley, DW Williamson, LL Scott, CP Elco, ... Science translational medicine 7 (308), 308ra158-308ra158, 2015 | 197 | 2015 |
| Staged development of long-lived T-cell receptor αβ TH17 resident memory T-cell population to Candida albicans after skin infection CO Park, X Fu, X Jiang, Y Pan, JE Teague, N Collins, T Tian, JT O'Malley, ... Journal of Allergy and Clinical Immunology 142 (2), 647-662, 2018 | 117 | 2018 |
| High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides A De Masson, JT O’Malley, CP Elco, SS Garcia, SJ Divito, EL Lowry, ... Science translational medicine 10 (440), eaar5894, 2018 | 104 | 2018 |
| Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial AS Paller, EL Simpson, EC Siegfried, MJ Cork, A Wollenberg, ... The Lancet 400 (10356), 908-919, 2022 | 96 | 2022 |
| Temporal induction pattern of STAT4 target genes defines potential for Th1 lineage-specific programming SR Good, VT Thieu, AN Mathur, Q Yu, GL Stritesky, N Yeh, JT O'Malley, ... The Journal of Immunology 183 (6), 3839-3847, 2009 | 90 | 2009 |
| Dupilumab provides favourable long‐term safety and efficacy in children aged≥ 6 to< 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa … MJ Cork, D Thaçi, LF Eichenfield, PD Arkwright, X Sun, Z Chen, ... British Journal of Dermatology 184 (5), 857-870, 2021 | 70 | 2021 |
| Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease SJ Divito, AT Aasebø, TR Matos, PC Hsieh, M Collin, CP Elco, ... The Journal of Clinical Investigation 130 (9), 4624-4636, 2020 | 68 | 2020 |
| Stat4 isoforms differentially regulate inflammation and demyelination in experimental allergic encephalomyelitis C Mo, W Chearwae, JT O'Malley, SM Adams, S Kanakasabai, CC Walline, ... The Journal of Immunology 181 (8), 5681-5690, 2008 | 57 | 2008 |
| Signal transducer and activator of transcription 4 limits the development of adaptive regulatory T cells JT O’Malley, S Sehra, VT Thieu, Q Yu, HC Chang, GL Stritesky, ... Immunology 127 (4), 587-595, 2009 | 56 | 2009 |
| STAT3/5-dependent IL9 overexpression contributes to neoplastic cell survival in mycosis fungoides PA Vieyra-Garcia, T Wei, DG Naym, S Fredholm, R Fink-Puches, ... Clinical Cancer Research 22 (13), 3328-3339, 2016 | 55 | 2016 |
| Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials G Yosipovitch, N Mollanazar, S Ständer, SG Kwatra, BS Kim, E Laws, ... Nature medicine 29 (5), 1180-1190, 2023 | 50 | 2023 |
| Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma P Vieyra-Garcia, JD Crouch, JT O’Malley, EW Seger, CH Yang, ... JCI insight 4 (1), 2019 | 50 | 2019 |
| STAT4 isoforms differentially regulate Th1 cytokine production and the severity of inflammatory bowel disease JT O'Malley, RD Eri, GL Stritesky, AN Mathur, HC Chang, H HogenEsch, ... The Journal of Immunology 181 (7), 5062-5070, 2008 | 49 | 2008 |
| Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis LA Beck, M Deleuran, R Bissonnette, M de Bruin-Weller, R Galus, ... American journal of clinical dermatology 23 (3), 393-408, 2022 | 48 | 2022 |
| Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial … A Blauvelt, E Guttman-Yassky, AS Paller, EL Simpson, MJ Cork, ... American journal of clinical dermatology 23 (3), 365-383, 2022 | 46 | 2022 |
| CD30+ lymphoproliferative disorders of the skin MB Sauder, JT O'Malley, NR LeBoeuf Hematology/Oncology Clinics 31 (2), 317-334, 2017 | 46 | 2017 |
